Mesoblast Limited announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.155 AUD | -1.70% | +7.44% | +272.58% |
Apr. 01 | ADRs End Higher; Connect Biopharma Climbs 26% | DJ |
Mar. 28 | ADRs End Lower; NuCana Slides 15% | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+272.58% | 889M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.81% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease